invest1 publisher
ST Pharm tops $50 million on an oligonucleotide order three times this year
ST Pharm signed three oligonucleotide contracts worth $182 million this year, each above $50 million, a size it did not reach once last year. Its earnings case now rests on commercial reorders, with the largest contract tied by industry estimates to a single Ionis drug, Tryngolza.
Publishers:en.sedaily.com
Reality
- Evidence55
- Adoption60
- Hype gap+10
- Incentives
- Insufficient
- Confidence55